- Home
- AQMS vs IMRN Comparison
AQMS vs IMRN Comparison
Compare AQMS & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQMS
- IMRN
- Stock Information
- Founded
- AQMS 2014
- IMRN 1994
- Country
- AQMS United States
- IMRN Australia
- Employees
- AQMS N/A
- IMRN N/A
- Industry
- AQMS Metal Fabrications
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- AQMS Industrials
- IMRN Health Care
- Exchange
- AQMS Nasdaq
- IMRN Nasdaq
- Market Cap
- AQMS 10.3M
- IMRN 9.2M
- IPO Year
- AQMS 2015
- IMRN N/A
- Fundamental
- Price
- AQMS $5.93
- IMRN $2.20
- Analyst Decision
- AQMS Buy
- IMRN
- Analyst Count
- AQMS 1
- IMRN 0
- Target Price
- AQMS $30.00
- IMRN N/A
- AVG Volume (30 Days)
- AQMS 2.6M
- IMRN 67.6K
- Earning Date
- AQMS 11-13-2025
- IMRN 08-29-2025
- Dividend Yield
- AQMS N/A
- IMRN N/A
- EPS Growth
- AQMS N/A
- IMRN N/A
- EPS
- AQMS N/A
- IMRN N/A
- Revenue
- AQMS N/A
- IMRN $4,777,422.00
- Revenue This Year
- AQMS N/A
- IMRN N/A
- Revenue Next Year
- AQMS $550.00
- IMRN N/A
- P/E Ratio
- AQMS N/A
- IMRN N/A
- Revenue Growth
- AQMS N/A
- IMRN 48.63
- 52 Week Low
- AQMS $3.37
- IMRN $1.50
- 52 Week High
- AQMS $34.84
- IMRN $2.73
- Technical
- Relative Strength Index (RSI)
- AQMS 56.15
- IMRN 74.15
- Support Level
- AQMS $3.75
- IMRN $1.87
- Resistance Level
- AQMS $8.25
- IMRN $1.95
- Average True Range (ATR)
- AQMS 1.15
- IMRN 0.07
- MACD
- AQMS 0.06
- IMRN 0.03
- Stochastic Oscillator
- AQMS 47.86
- IMRN 84.86
About AQMS Aqua Metals Inc.
Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting, and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.